N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aR,6aS)-2-methyloctahydrocyclopenta(c)pyrrol-5-yl)methoxy)-4-quinazolinamine
| CAS No. | 781613-23-8 |
|---|---|
| MDL No. | MFCD28501234 |
| MF | C24H25Cl2FN4O2 |
| MW | 491.40 |
| InChI Key | HVXKQKFEHMGHSL-GOOCMWNKSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Tesevatinib is a quinazoline derivative substituted at positions 4, 6, and 7 with (3,4-dichloro-2-fluorophenyl)amino, methoxy, and [(3aR,5R,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy groups, respectively. It is a multi-target tyrosine kinase inhibitor acting on EGFR, ErbB2, KDR, Flt4, and EphB4, with anti-cancer properties. It functions as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, and an epidermal growth factor receptor antagonist. It belongs to the classes of quinazolines, aromatic ethers, monofluorobenzenes, dichlorobenzenes, secondary and tertiary amino compounds, and diethers.
| CAS No. | 781613-23-8 |
|---|---|
| Product Name | N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-(((3aR,6aS)-2-methyloctahydrocyclopenta(c)pyrrol-5-yl)methoxy)-4-quinazolinamine |
Biological Targets
EPHB4·EGFR·ERBB2
Associated Conditions
breast cancer·autosomal recessive polycystic kidney disease·non-small cell lung carcinoma·glioblastoma multiforme·Autosomal dominant polycystic kidney disease·
* The information provided here is compiled from public sources and is for reference only.
